TOP TEN perturbations for 38500_at (Homo sapiens)

Organism: Homo sapiens
Gene: 38500_at
Selected probe(set): 214658_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 38500_at (214658_at) across 6674 perturbations tested by GENEVESTIGATOR:

brefeldin A study 1 (0.5ug/ml; p53HCT116) / untreated p53HCT116 cell sample

Relative Expression (log2-ratio):4.861768
Number of Samples:2 / 3
Experimental brefeldin A study 1 (0.5ug/ml; p53HCT116)
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated p53HCT116 cell sample
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

brefeldin A study 1 (0.5ug/ml; HCT 116) / untreated HCT 116 cell sample

Relative Expression (log2-ratio):4.7372046
Number of Samples:3 / 3
Experimental brefeldin A study 1 (0.5ug/ml; HCT 116)
Human colon carcinoma cell line HCT116 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated HCT 116 cell sample
Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

tunicamycin study 2 (2ug/ml; p53HCT116) / untreated p53HCT116 cell sample

Relative Expression (log2-ratio):4.452711
Number of Samples:3 / 3
Experimental tunicamycin study 2 (2ug/ml; p53HCT116)
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 2 ug/ml tunicamycin for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated p53HCT116 cell sample
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

tunicamycin study 2 (2ug/ml; HCT 116) / untreated HCT 116 cell sample

Relative Expression (log2-ratio):3.9029007
Number of Samples:3 / 3
Experimental tunicamycin study 2 (2ug/ml; HCT 116)
Human colon carcinoma cell line HCT116 was treated with 2 ug/ml tunicamycin for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated HCT 116 cell sample
Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

tunicamycin study 2 (2ug/ml; HCT 116 DICER1(-/-)) / untreated HCT 116 DICER1(-/-) cell sample

Relative Expression (log2-ratio):3.5957155
Number of Samples:3 / 3
Experimental tunicamycin study 2 (2ug/ml; HCT 116 DICER1(-/-))
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 was treated with 2 ug/ml tunicamycin for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated HCT 116 DICER1(-/-) cell sample
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 by was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

influenza virus study 11 (A/H5N3) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):2.959156
Number of Samples:3 / 3
Experimental influenza virus study 11 (A/H5N3)
Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F119/3/1997(H5N3). Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

influenza virus study 10 (A/H5N2) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):2.8051653
Number of Samples:3 / 3
Experimental influenza virus study 10 (A/H5N2)
Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F189/07/2004(H5N2). Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

kidney transplantation study 15 (8 week) / normal monocyte (CD14+) sample

Relative Expression (log2-ratio):-2.5252628
Number of Samples:2 / 5
Experimental kidney transplantation study 15 (8 week)
CD14+ monocyte samples derived from kidney transplant patients 8 weeks post-transplantation. Samples were collected 8 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control normal monocyte (CD14+) sample
CD14+ monocyte samples derived from healthy control subjects.

Huntington's disease study 16 (batch L) / Parkinson's disease study 32 (IPD)

Relative Expression (log2-ratio):2.332426
Number of Samples:8 / 205
Experimental Huntington's disease study 16 (batch L)
Blood samples obtained from Huntington´s disease patients (batch L).
Control Parkinson's disease study 32 (IPD)
Blood samples obtained from patients with idiopathic Parkinson's disease (IPD). All patients were treated with dopaminergic medication and met United Kingdom Parkinson’s Disease Society Brain Bank Criteria except that positive family history was not regarded as an exclusion criterion. Patients that were suspected of having possible secondary causes for parkinsonism such as use of neuroleptic agents, and patients meeting criteria for atypical PD syndromes and who had SPECT data available that showed scans without evidence of dopaminergic deficits were excluded.

Huntington's disease study 16 (batch L) / control blood sample

Relative Expression (log2-ratio):2.3118706
Number of Samples:8 / 231
Experimental Huntington's disease study 16 (batch L)
Blood samples obtained from Huntington´s disease patients (batch L).
Control control blood sample
Blood samples obtained from healthy subjects including nonconsanguineous controls from families of patients.